Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04071327 · ClinicalTrials.gov registry record

Pulmonary Hypertension Association Registry

A clinical trial of Pulmonary Hypertension and Pulmonary Arterial Hypertension, sponsored by Pulmonary Hypertension Association.

Recruiting
Registry status
3,000
Enrollment target
20
Study locations

NCT04071327: Recruiting study of Pulmonary Hypertension and Pulmonary Arterial Hypertension, sponsored by Pulmonary Hypertension Association.

NCT04071327 is a study of Pulmonary Hypertension and Pulmonary Arterial Hypertension that is actively recruiting participants, run by Pulmonary Hypertension Association. The registered enrollment target is 3,000 participants, above the 572-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (424% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04071327, a study of Pulmonary Hypertension and Pulmonary Arterial Hypertension, is actively recruiting participants, sponsored by Pulmonary Hypertension Association.

RECRUITING
Registry status
3,000 participants
Enrollment target
20
Study locations

Study Summary

The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH are treated according to recommended guidelines, and to see if there are certain factors that can lead to better or worse outcomes. PHAR will include information about people with PAH and CTEPH in the U.S. who are seen at participating PHA-accredited PH Care Centers. PHAR contains data about patient care and outcomes. Specifically, data in the PHAR includes information on diagnosis; clinical status; socioeconomic status; diagnosis test results; body size; treatment information; interest in participating in clinical trials; family health and social history; and information about smoking, alcohol, or drug use. Participants are followed over time, and provide updates such as changes in therapy, how often participants need to go to the hospital, and survival. Such information may help healthcare providers provide better care.

Primary Outcome

PAH guideline-recommended diagnostics assessed include chest radiography, echocardiogram, ventilation-perfusion (V/Q) scan, pulmonary function tests, overnight oximetry, and right heart catheterization and identified as either "completed" or "not completed"

Study Locations (20)

California

  • UC Davis Health - Sacramento
  • UCSF Medical Center - San Francisco
  • UCSF Benioff Children's Hospital - San Francisco
  • Cottage Health System - Santa Barbara Pulmonary Associates - Santa Barbara
  • Stanford University - Stanford

Colorado

  • Children's Hospital Colorado - Aurora
  • UC Health - Anschutz Medical Campus - Aurora

Louisiana

  • Ochsner Medical Center - Jefferson
  • LSU Healthcare Network Clinic - New Orleans

Maryland

  • University of MD Medical Group, PA - Baltimore
  • Johns Hopkins University - Baltimore

Arizona

  • Arizona Pulmonary Specialists, Ltd. - Phoenix

Connecticut

  • University of Connecticut Health - Farmington

Florida

  • Mayo Clinic Florida - Jacksonville

Georgia

  • Northside Hospital - Atlanta

Trial Details

FieldValue
Enrollment Target 3,000 participants
Start Date 2015-10
Est. Completion 2025-12

What NCT04071327 shows while recruiting

NCT04071327 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 572-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (424% higher).

The record links to 3 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 0 interventions.

NCT04071327 names 20 study sites across 13 states, led by California, Colorado, Louisiana.

Frequently Asked Questions

What is clinical trial NCT04071327 about?

NCT04071327 is a clinical study titled "Pulmonary Hypertension Association Registry". The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Ce...

What is the current status of trial NCT04071327?

This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2015-10. Estimated completion is 2025-12.

What conditions does trial NCT04071327 study?

This clinical trial studies the following conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension.

Who is sponsoring clinical trial NCT04071327?

This trial is sponsored by Pulmonary Hypertension Association, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04071327 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04071327's enrollment target sits among peer trials

3,000 5th of 72 higher than 67 of 72 other Pulmonary Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004847 · 3,000 participants · Phase 1

    Diagnosis of Pheochromocytoma

  • NCT00478712 · 3,000 participants

    Hirschsprung Disease Genetic Study

  • NCT00579566 · 3,000 participants

    Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

  • NCT00816114 · 3,000 participants

    Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT04071327, the US trial registry maintained by the National Library of Medicine. NCT04071327 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.